

## **Appendix P Methods of blood analysis and quality control**

*Original authors: Sonja Nicholson, Lorna Cox, Stephen Young, Peter Winship, Chris Bates and Ann Prentice*

*Updated by: Sonja Nicholson, Lorna Cox, Stephen Young, Amanda McKillion*

### **P.1 Introduction**

Samples of coagulated and ethylenediaminetetraacetate (EDTA) anticoagulated blood were sent directly by post to the Department of Haematology and Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge (Addenbrooke's) after their collection. Serum samples were obtained by centrifugation of the coagulated blood sample.

The following assays were conducted at Addenbrooke's:

- full blood count including haemoglobin and haematocrit (see section P.2.1)
- serum C-reactive protein, using a high-sensitivity assay (see section P.2.2)
- serum vitamin B<sub>12</sub> (see section P.2.3)
- serum Total, HDL and LDL cholesterol (see section P.2.4)
- serum triglycerides (triacylglycerols) (see section P.2.5)

Samples of coagulated, EDTA anticoagulated and lithium heparin anticoagulated blood were collected and stored in a cool box, at approximately 4°C, and delivered to a local processing field laboratory within two hours of collection. The field laboratories processed blood samples into whole blood, red cells, plasma, serum and metaphosphoric acid stabilised plasma portions. The metaphosphoric acid had been previously prepared and aliquotted at HNR and delivered by courier on dry ice to each field laboratory. Blood sample sub-fractions were stored frozen at a maximum of -20°C (typically at -40°C) at field laboratories for a period of six to eight weeks, before the samples were transported to HNR on dry ice, where they were stored frozen, at -80°C, until further subdivided and analysed.

The assays described in Sections P.2.6 to P.2.16 (and listed below) were conducted at HNR:

- plasma ferritin (see section P.2.6)
- plasma soluble transferrin receptors (see section P.2.7)
- plasma vitamin C (see section P.2.8)
- ETKAC for thiamin status (see section P.2.9)
- EGRAC for riboflavin status (see section P.2.10)
- plasma vitamin B<sub>6</sub> (PLP and PA) (see section P.2.11)
- plasma total homocysteine (see section P.2.12)
- plasma retinol (see section P.2.13)
- plasma retinyl palmitate (see section P.2.13)
- plasma  $\alpha$ -tocopherol (see section P.2.13)
- plasma  $\gamma$ -tocopherol (see section P.2.13)
- plasma individual carotenoids;  $\alpha$ -carotene,  $\beta$ -carotene,  $\alpha$ -cryptoxanthin,  $\beta$ -cryptoxanthin, lycopene, lutein and zeaxanthin (see section P.2.13)
- plasma 25-hydroxyvitamin D (see section P.2.14)
- plasma creatinine (see section P.2.15)
- plasma selenium (see section P.2.16)
- plasma zinc (see section P.2.16)

Serum and whole blood folate concentrations in NDNS Rolling Programme (NDNS RP) blood samples were measured at the Centre for Disease Control (CDC) in Atlanta, USA. Folate analysis has been delayed; however folate results will be published as soon as available. Details of analytical methods for the analysis of folate and quality control data will be published alongside the folate results.

Appendix W provides details for analytes that were measured in the NDNS RP blood samples but are not included in the present report. However, their data will be deposited at the UK Data Archive together with data for the other analytes presented in this report.

## **P.2 Analysis of blood samples**

Details of the method of analysis and the associated quality control (QC) procedures for each analyte are given in sections P.2.1 to P.2.16. Where appropriate, the results of these procedures are also shown. Internal quality control samples were run in every batch to assess assay precision for each analyte; results are tabulated below. Accuracy was assessed by comparisons with target values (determined by the manufacturer using appropriate reference materials) and/or results obtained by other laboratories by taking part in EQAS (external quality assessment schemes) for those analytes where such schemes were available.

### **P.2.1 Full blood count including haemoglobin and haematocrit**

Full Blood Count was analysed on a Beckman Coulter LH700 series analyser which mainly uses the Coulter Principle<sup>1,2</sup> to count the red blood cells, mean cell volume (MCV), white blood cells and platelet counts. Haemoglobin was measured by photometric measurement. Other parameters such as the mean cell haemoglobin (MCH), haematocrit (HCT) and red cell distribution width (RDW) were calculated from the above measured parameters.


Haemoglobin was measured spectrophotometrically at 525nm by a photocell in a sample that was diluted 1:256 (final) with isotonic diluent and lysing solution. The red cells were destroyed with a lysing agent releasing the haemoglobin into solution, which enabled the white blood cell count to be estimated using the Coulter Principle (impedance counting of the white blood cells)<sup>1,2</sup> without interference by red cells. The same lysing reagent also converted the haemoglobin to cyanmethaemoglobin.




#### *P.2.1.1 Quality controls for full blood count including haemoglobin and haematocrit*




Quality of results was checked using Addenbrooke's internal controls at regular intervals and also assessed externally through UKNEQAS. NEQAS results are compared against the All Laboratories Trimmed Mean (ALTM) calculated for laboratories in the NEQAS scheme using the same analyser and method as that used by Addenbrooke's. Figures P.1 to P.4 show illustrative UKNEQAS overall performance results for full blood counts including haemoglobin and haematocrit for the periods covering analysis of samples for Years 1 to 4 of the NDNS RP. Results

within the white area of the charts indicate acceptable performance as determined by UKNEQAS. “Performance index” is derived by the NEQAS administrators as a function of the deviation of the laboratory from the consensus mean. The dark shaded area indicates unacceptable performance and the paler area indicates a borderline situation.


**Figure P.1 Illustrative overall performance charts for UKNEQAS for Year 1 of the NDNS RP**













**Figure P.2 Illustrative overall performance charts for UKNEQAS for Year 2 of the NDNS RP**


















**Figure P.3 Illustrative overall performance charts for UKNEQAS for Year 3 of the NDNS RP**













**Figure P.4 Illustrative overall performance charts for UKNEQAS for Year 4 of the NDNS RP**







### **P.2.2 Serum C-reactive protein (CRP)**

C-reactive protein (CRP) was assayed using a high-sensitivity assay on a Dade Behring Dimension RXL Clinical Chemistry Analyser. The CRP method is based on a particle enhanced turbidimetric immunoassay (PETIA) technique, giving high sensitivity by extending the detection range down to 1.0mg/L. Latex particles coated with antibody to CRP aggregate in the presence of CRP in the sample. The increase in turbidity that accompanies aggregation is proportional to the CRP concentration.

#### *P.2.2.1 Internal quality controls for CRP*

The performance statistics in Tables P.1-P.4 were calculated using data from two or three different reagent lots in order to include batch to batch variation. Table P.1 shows imprecision data produced from a combination of two typical months in Year 1 (01/05/2008-30/06/2008) over six instruments using two reagents. Table P.2 shows imprecision data produced from a typical month in Year 2 (January 2010) using three reagents. Table P.3 shows imprecision data produced from three typical months in Year 3 (01/09/2010 – 30/11/2010) using three reagents. Table P.4 shows imprecision data produced from a period covering analysis of Year 4 samples, using five reagents.

**Table P.1 Internal quality controls for C-reactive Protein (CRP) for Year 1 of the NDNS RP**

	<b>QC Lot No 0506314</b>	<b>QC Lot No 0704214</b>
Mean (mg/L)	15.56	71.30
SD	0.58	2.28
% CV	3.73	3.20
Data points included	141	151



**Table P.2 Internal quality controls for C-reactive Protein (CRP) for Year 2 of the NDNS RP**

	QC Lot No 29743	QC Lot No 991179
Mean (mg/L)	7.55	87.30
SD	0.40	3.50
% CV	5.30	4.01
Data points included	360	341

**Table P.3 Internal quality controls for C-reactive Protein (CRP) for Year 3 of the NDNS RP**

	QC Lot No 29753	QC Lot No 35282
Mean (mg/L)	7.88	81.80
SD	0.46	2.87
% CV	5.80	3.51
Data points included	1098	1120

**Table P.4 Internal quality controls for C-reactive Protein (CRP) for Year 4 of the NDNS RP**

	QC Lot No 29773	QC Lot No 29783
Mean (mg/L)	7.59	7.14
SD	0.537	0.250
% CV	7.1	3.5
Data points included	3839	1040
Used	01/07/2011 to 29/05/2012	16/05/2012 to 31/08/2012

	QC Lot No 35312	QC Lot No 35322	QC Lot No 35332
Mean (mg/L)	88.18	81.47	85.96
SD	3.943	2.318	3.828
% CV	4.5	2.8	4.5
Data points included	1798	669	2297
Used	01/07/2011 to 31/08/2012	23/11/2011 to 06/02/2012	16/02/2012 to 31/08/2012


#### *P.2.2.2 External quality controls for CRP*

External quality control was achieved through the UKNEQAS CRP scheme which distributes samples to a large number of laboratories for comparison of the results obtained.


The graphs of bias index and overall MRBIS (Mean Rolling Bias Index Score) versus distribution reproduced in figures P.5-P.6 show the laboratory's bias relative to the All Laboratory Trimmed Mean CRP concentration measured in the sample; these graphs are included by kind permission of the Department of Clinical Biochemistry, Addenbrooke's Hospital and UKNEQAS for Years 3 and 4 of the NDNS RP. Similar graphs are not available for previous years.

A score of <50 is "ideal"; 50-100 is "good" and 100-200 "adequate" for clinical purposes.

**Figure P.5 NEQAS performance for CRP assay for Year 3 of the NDNS RP**



**Figure P.6 NEQAS performance for CRP assay for Year 4 of the NDNS RP**



### **P.2.3 Serum vitamin B<sub>12</sub>**

The ADVIA Centaur B<sub>12</sub> assay is a competitive immunoassay using direct chemiluminescence. Vitamin B<sub>12</sub> from a participant's sample competes with vitamin B<sub>12</sub> labelled with acridinium ester for a limited amount of labelled intrinsic factor. The intrinsic factor is covalently bound to paramagnetic particles. The assay uses a releasing agent (sodium hydroxide) and dithiothreitol (DTT) to release the B<sub>12</sub> from the endogenous binding proteins in the sample.

#### *P.2.3.1 Internal quality controls for vitamin B<sub>12</sub>*

The performance statistics in Tables P.5-P.8 were calculated using data from two or three different reagent lots in order to include batch to batch variation. Table P.5

shows two lots of Lyphocek QC data produced for Year 1. Data in the upper section of the table is for the period 18/02/2008-16/07/2008 and data in the lower section of the table is for the period 16/07/2008-22/05/2009. Table P.6 shows two lots of Lyphocek QC data produced for Year 2. Data in the upper section of the table is for the period 08/07/2009-01/05/2010 and data in the lower section of the table is for the period 01/05/2010-09/08/2010. Table P.7 shows imprecision data produced from a combination of five typical months in Year 3 (01/08/2010-31/12/2010) over two instruments using two reagents. Table P.8 shows imprecision data for a period covering the analysis of Year 4 samples, over two instruments using two reagents.

**Table P.5 Internal quality controls for vitamin B<sub>12</sub> for Year 1 of the NDNS RP**

	<b>QC Lot No 40181</b>	<b>QC Lot No 40182</b>	<b>QC Lot No 40183</b>
Mean	332	577	898
SD	25.9	54.4	68.6
% CV	7.8	9.4	7.6
Data points included	115	112	124
	<b>QC Lot No 40201</b>	<b>QC Lot No 40202</b>	<b>QC Lot No 40203</b>
Mean	398	665	1127
SD	39.9	51.6	80.0
% CV	10.0	7.8	7.1
Data points included	433	422	467

**Table P.6 Internal quality controls for vitamin B<sub>12</sub> for Year 2 of the NDNS RP**

	<b>QC Lot No 40201</b>	<b>QC Lot No 40202</b>	<b>QC Lot No 40203</b>
Mean	396	658	1120
SD	35.2	48.1	82.9
% CV	8.9	7.3	7.4
Data points included	559	555	556
	<b>QC Lot No 40231</b>	<b>QC Lot No 40232</b>	<b>QC Lot No 40233</b>
Mean	354	651	1373
SD	30.0	46.9	82.9
% CV	8.4	7.2	6.0
Data points included	149	156	125

**Table P.7 Internal quality controls for vitamin B<sub>12</sub> for Year 3 of the NDNS RP**

	<b>QC Lot No 40231</b>	<b>QC Lot No 40232</b>	<b>QC Lot No 40233</b>	<b>QC Lot No 43170</b>
Mean (µg/L)	345	677	1403	131
SD	24.4	38.0	105.4	19.9
% CV	7.06	5.86	7.51	15.17
Data points included	347	338	336	291

**Table P.8 Internal quality controls for vitamin B<sub>12</sub> for Year 4 of the NDNS RP**

	<b>QC Lot No 40241</b>	<b>QC Lot No 40242</b>	<b>QC Lot No 40243</b>	<b>QC Lot No 43170</b>
Mean (µg/L)	401	562	1307	138
SD	30.9	38.6	86.1	23.2
% CV	7.70	6.87	6.59	16.77
Data points included	1137	547	647	481
Used	01/07/2011 to 26/07/2012	01/07/2011 to 12/01/2012	01/07/2011 to 20/02/2012	01/07/2011 to 30/12/2011

	<b>QC Lot No 40261</b>	<b>QC Lot No 40262</b>	<b>QC Lot No 40263</b>	<b>QC Lot No 43180</b>
Mean (µg/L)	400	567	1114	130
SD	27.3	37.5	85.3	24.6
% CV	6.83	6.61	7.66	18.99
Data points included	94	243	267	314
Used	27/07/2012 to 31/08/2012	12/06/2012 to 31/08/2012	28/05/2012 to 31/08/2012	03/01/2012 to 17/04/2012

	<b>QC Lot No 40251</b>	<b>QC Lot No 40252</b>	<b>QC Lot No 40253</b>	<b>QC Lot No 45200</b>
Mean (µg/L)		557	1120	130
SD		34.9	60.6	18.8
% CV		6.26	5.41	14.44
Data points included		452	269	366
Used	Not used	12/01/2012 to 11/06/2012	20/02/2012 to 30/05/2012	18/04/2012 to 31/08/2012


### P.2.3.2 External quality controls for vitamin B<sub>12</sub>

Quality control was achieved through the UK NEQAS Haematinics scheme. Charts relating to performance during Years 1 to 4 are reproduced below with permission of the Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital (Addenbrooke's), and the NEQAS Haematinics Scheme organisers.


Figures P.7-P.10 show the bias relative to the target concentration during the years when NDNS samples were being analysed. Filled circles represent Addenbrookes' results; open circles represent results from other laboratories which use the same method. DI (Deviation Index) relates to the distribution of results from all laboratories and indicates by how many standard deviations a result differs from the All Laboratory Trimmed Mean. Better performance is indicated by lighter shading.

A small DI (+ or -) indicates close agreement. Mean Running Bias Index Score (MRBIS) is the mean of the 10 most recent bias estimates; results of 0.54 (Year 1), 0.05 (Year 2), -0.06 (Year 3) and 0.36 (Year 4) indicate that there was good overall agreement between Addenbrooke's results and the target concentrations.


**Figure P.7 Illustrative overall performance charts for UKNEQAS for Year 1 of the NDNS RP for vitamin B<sub>12</sub>**



**Figure P.8 Illustrative overall performance charts for UKNEQAS for Year 2 of the NDNS RP for vitamin B<sub>12</sub>**




**Figure P.9 Illustrative overall performance charts for UKNEQAS for Year 3 of the NDNS RP for vitamin B<sub>12</sub>**





**Figure P.10 Illustrative overall performance charts for UKNEQAS for Year 4 of the NDNS RP for vitamin B<sub>12</sub>**



#### **P.2.4 Serum total, high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol**

The total cholesterol method on the Siemens Dimension analyser is based on the principle first described by Stadtman<sup>3</sup> and later adapted by other workers, including Rautela and Liedtke.<sup>4</sup> Cholesterol esterase (CE) catalyses the hydrolysis of cholesterol esters to produce free cholesterol which, along with pre-existing free cholesterol, is oxidised in a reaction catalysed by cholesterol oxidase (CO) to form cholest-4-ene-3-one and hydrogen peroxide. In the presence of horseradish peroxidase (HPO), the hydrogen peroxide thus formed is used to oxidize N,N-diethylaniline-HCl/4-aminoantipyrine (DEA-HCl/AAP) to produce a chromophore that absorbs at 540 nm.

The AHDL cholesterol assay is a homogeneous method for directly measuring HDL cholesterol concentrations.

The method is based on accelerating the reaction of cholesterol oxidase (CO) with non-HDL unesterified cholesterol and dissolving HDL selectively using a specific detergent. In the first reaction, non-HDL unesterified cholesterol is subject to a

cholesterol oxidase reaction and the peroxide generated is consumed by a peroxidase reaction with DSBmT yielding a colourless product. The second reagent consists of a detergent capable of solubilising HDL specifically, cholesterol esterase (CE) and chromagenic coupler to develop colour for the quantitative determination of HDL-C.

#### *P.2.4.1 Internal quality controls for total cholesterol*

The performance statistics in Tables P.9-P.12 were calculated using data from two or three different reagent lots in order to include batch to batch variation. Table P.9 shows imprecision data produced from a combination of two typical months in Year 1 (01/12/2008-10/02/2009) over six instruments. Table P.10 shows imprecision data produced from a typical month in Year 2 (January 2010). Table P.11 shows imprecision data produced from a combination of three typical months in Year 3 (01/09/2010-30/11/2010) over six instruments using two reagents. Table P.12 shows imprecision data for a period covering the analysis of Year 4 samples; over six instruments using two reagents

**Table P.9 Internal quality controls for total cholesterol for Year 1 of the NDNS RP**

	QC Lot No 46381	QC Lot No 46383
Mean (mmol/L)	2.34	6.58
SD	0.069	0.167
% CV	2.9	2.5
Data points included	869	943

**Table P.10 Internal quality controls for total cholesterol for Year 2 of the NDNS RP**

	QC Lot No 46381	QC Lot No 46383
Mean (mmol/L)	2.35	6.53
SD	0.105	0.126
% CV	4.5	1.9
Data points included	389	147

**Table P.11 Internal quality controls for total cholesterol for Year 3 of the NDNS RP**

	QC Lot No 46401	QC Lot No 46403
Mean (mmol/L)	2.63	6.75
SD	0.088	0.159
% CV	3.3	2.4
Data points included	1115	1209

**Table P.12 Internal quality controls for total cholesterol for Year 4 of the NDNS RP**

	QC Lot No 46433
Mean (mmol/L)	6.48
SD	0.104
% CV	1.6
Data points included	141
Used	01/07/2011 to 12/07/2011

	QC Lot No 46441	QC Lot No 46443
Mean (mmol/L)	2.65	6.69
SD	0.090	0.158
% CV	3.4	2.4
Data points included	4693	3447
Used	01/07/2011 to 03/07/2012	12/07/2011 to 19/04/2012

	QC Lot No 46461	QC Lot No 46463
Mean (mmol/L)	2.71	6.66
SD	0.081	0.144
% CV	3.0	2.2
Data points included	732	1575
Used	01/07/2012 to 31/08/2012	19/04/2012 to 31/08/2012

#### *P.2.4.2 Internal quality controls for HDL cholesterol*

The performance statistics in Tables P.13-P.16 were calculated using data from two or three different reagent lots in order to include batch to batch variation. Table P.13 shows imprecision data produced from a combination of two typical months in Year 1 (01/05/2008-30/06/2008) over four instruments. Table P.14 shows imprecision data produced from a typical month in Year 2 (January 2010). Table P.15 shows imprecision data produced from a combination of three typical months in Year 3 (01/09/2010-30/11/2010) over four instruments using three reagents. Table P.16 shows imprecision data for a period covering the analysis of Year 4 samples, over four instruments using three reagents.

**Table P.13 Internal quality controls for HDL cholesterol for Year 1 of the NDNS RP**

	QC Lot No	QC Lot No 46383
Mean (mmol/L)	0.91	2.03
SD	0.04	0.11
% CV	4.4	4.8
Data points included	140	149

**Table P.14 Internal quality controls for HDL cholesterol for Year 2 of the NDNS RP**

	QC Lot No 46381	QC Lot No 46383
Mean (mmol/L)	0.93	2.15
SD	0.03	0.09
% CV	3.2	4.2
Data points included	232	237

**Table P.15 Internal quality controls for HDL cholesterol for Year 3 of the NDNS RP**

	QC Lot No 46401	QC Lot No 46403
Mean (mmol/L)	0.95	1.91
SD	0.05	0.08
% CV	4.9	4.0
Data points included	738	862

**Table P.16 Internal quality controls for high density lipoprotein cholesterol for Year 4 of the NDNS RP**

	QC Lot No 46433
Mean (mmol/L)	1.90
SD	0.074
% CV	3.9
Data points included	96
Used	01/07/2011 to 12/07/2011

	QC Lot No 46441	QC Lot No 46443*
Mean (mmol/L)	0.69	1.78
SD	0.045	0.140
% CV	6.4	7.9
Data points included	2921	2328
Used	01/07/2011 to 03/07/2012	12/07/2011 to 19/04/2012

	QC Lot No 46461	QC Lot No 46463*
Mean (mmol/L)	0.76	1.65
SD	0.029	0.101
% CV	3.8	6.1
Data points included	456	1006
Used	01/07/2012 to 31/08/2012	19/04/2012 to 31/08/2012

\*46443 and 46463 contains data obtained on material whose integrity could not be guaranteed.

#### *P.2.4.3 External quality controls for total and HDL cholesterol*

External quality control was achieved through the Randox International Quality Assessment Scheme (RIQAS); NEQAS pooled samples are unsuitable for the methods used by the Siemens Dimension instruments. Table P.17 indicates the percentage deviation of results obtained by Addenbrooke's Hospital Dept of Clinical Biochemistry from the target concentration. These have been calculated at HNR

from raw data kindly supplied by RIQAS for Years 2, 3 and 4 of the NDNS RP and are included with the permission of the laboratory and the Scheme organisers.

**Table P.17 RIQAS results for lipid analyses - deviation from target concentration**

Analyte		Year 2	Year 3	Year 4
Cholesterol	mean % deviation	-1.65	-1.71	-2.39
	SD	3.49	2.00	2.07
HDL-Cholesterol	mean % deviation	-4.91	0.20	-1.34
	SD	4.11	14.48	4.89

### **P.2.5 Serum triglycerides (triacylglycerols)**

The triglycerides (triacylglycerols) method is based on an enzymatic procedure in which a combination of enzymes are employed for the measurement of serum or plasma triglycerides (triacylglycerols). The sample is incubated with lipoprotein lipase (LPL) enzyme reagent that converts triglycerides (triacylglycerols) into free glycerol and fatty acids. Glycerol kinase (GK) catalyses the phosphorylation of glycerol by adenosine-5-triphosphate (ATP) to glycerol-3-phosphate. Glycerol-3-phosphate-oxidase oxidises glycerol-3-phosphate to dihydroxyacetone phosphate and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). The catalytic action of peroxidase (POD) forms quinoneimine from H<sub>2</sub>O<sub>2</sub>, aminoantipyrine and 4-chlorophenol.

The change in absorbance due to the formation of quinoneimine is directly proportional to the total amount of glycerol and its precursors in the sample and is measured using a bichromatic (510nm, 700nm) endpoint technique.

#### *P.2.5.1 Internal quality controls for serum triglycerides (triacylglycerols)*

The performance statistics in Tables P.18-P.21 were calculated using data from two or three different reagent lots in order to include batch to batch variation. Table P.18 shows imprecision data produced from a combination of two typical months in Year 1 (01/05/2008-30/06/2008). Table P.19 shows imprecision data produced from a typical month in Year 2 (January 2010). Table P.20 shows imprecision data produced from a combination of three typical months in Year 3 (01/09/2010-

30/11/2010) over four instruments using three reagents. Table P.21 shows imprecision data in Year 4.

**Table P.18 Internal quality controls for serum triglycerides (triacylglycerols) for Year 1 of the NDNS RP**

	QC Lot No 46381	QC Lot No 46383
Mean (mmol/L)	0.89	2.22
SD	0.08	0.13
% CV	9.0	5.9
Data points included	150	152

**Table P.19 Internal quality controls for serum triglycerides (triacylglycerols) for Year 2 of the NDNS RP**

	QC Lot No 46381	QC Lot No 46383
Mean (mmol/L)	0.73	2.28
SD	0.05	0.07
% CV	6.8	3.1
Data points included	304	297

**Table P.20 Internal quality controls for serum triglycerides (triacylglycerols) for Year 3 of the NDNS RP**

	QC Lot No 46401	QC Lot No 46403
Mean (mmol/L)	0.88	2.42
SD	0.04	0.06
% CV	4.3	2.6
Data points included	807	820

**Table P.21 Internal quality controls for triglyceride for Year 4 of the NDNS RP**

	QC Lot No 46433
Mean (mmol/L)	2.38
SD	0.050
% CV	2.1
Data points included	100
Used	01/07/2011 to 12/07/2011

	QC Lot No 46441	QC Lot No 46443
Mean (mmol/L)	1.00	2.40
SD	0.067	0.076
% CV	6.7	3.2
Data points included	3227	2289
Used	01/07/2011 to 03/07/2012	12/07/2011 to 19/04/2012

	QC Lot No 46461	QC Lot No 46463
Mean (mmol/L)	0.88	2.35
SD	0.053	0.075
% CV	6.0	3.2
Data points included	459	1046
Used	01/07/2012 to 31/08/2012	19/04/2012 to 31/08/2012

#### *P.2.5.2 External quality controls for serum triglycerides (triacylglycerols)*

External quality control was achieved through RIQAS (Randox International Quality Assurance Scheme). Table P.22 indicates the percentage deviation of results obtained by Addenbrooke's Hospital Dept of Clinical Biochemistry from the target concentration. These have been calculated at HNR from raw data kindly supplied by RIQAS for Years 2, 3 and 4 of the NDNS RP and are included with the permission of the laboratory and the Scheme organisers.



## P.22 RIQAS results for Triglycerides: deviation from target concentration

	Year 2	Year 3	Year 4
mean % deviation	-2.90	-2.55	-2.83
sd	5.61	5.90	4.93

## P.2.6 Plasma ferritin

This assay was performed using the Siemens BN ProSpec® system which uses particle-enhanced immunonephelometry for the quantitative determination of ferritin in heparinised human plasma. Polystyrene particles coated with specific antibodies to human ferritin are agglutinated when mixed with samples containing human ferritin. The intensity of the scattered light in the nephelometer is proportional to the ferritin content of the sample; therefore, the ferritin concentration can be quantitated by comparison to dilutions of a calibrant of known concentration.

### P.2.6.1 Internal quality controls for plasma ferritin

Control serum was obtained commercially containing low, medium and high concentrations of ferritin and was included in each run. Results were checked to ensure they fell within the manufacturer's target range. The results in Tables P.23-P.26 indicate good between-batch consistency for ferritin results during Years 1 to 4.

**Table P.23 Internal quality controls for ferritin for Year 1 of the NDNS RP**

Year 1	Low			Medium			High			
Mean(µg/l)	38.9	40.9	38.5	99.0	97.5	98.9	143.4	152.8	150.8	164.6
SD (µg/l)	2.3	3.0	3.3	4.5	4.7	3.1	7.1	10.2	6.3	5.7
% CV	6.0	7.3	8.6	4.5	4.8	3.1	5.0	6.6	4.2	3.5
N	38	21	21	13	42	21	14	24	17	15

**Table P.24 Internal quality controls for ferritin for Year 2 of the NDNS RP**

Year 2	Low	Medium	High
Mean( $\mu\text{g/l}$ )	37.5	114.1	153.7
SD ( $\mu\text{g/l}$ )	3.0	10.2	12.3
% CV	8.1	8.9	8.0
N	15	14	15

**Table P.25 Internal quality controls for ferritin for Year 3 of the NDNS RP**

Year 3	Low		Medium		High	
Mean ( $\mu\text{g/l}$ )	37.6	38.9	98.6	92.6	155.2	140.9
SD ( $\mu\text{g/l}$ )	3.7	3.9	9.1	6.6	15.0	12.6
CV (%)	9.8	10.1	9.2	7.2	9.6	8.9
N	11	17	15	14	13	17

**Table P.26 Internal quality controls for ferritin for Year 4 of the NDNS RP**

Year 4	Low		Medium		High	
Mean ( $\mu\text{g/l}$ )	42.0	39.3	98.3	96.0	143.9	141.4
SD ( $\mu\text{g/l}$ )	3.4	7.1	6.5	3.8	6.1	6.0
CV (%)	8.1	7.1	6.6	4.0	4.3	4.2
N	11	17	17	10	17	11


### *P.2.6.2 External quality controls for plasma ferritin*

External quality assessment was through the UKNEQAS Haematinics scheme.


Figures P.11-P.14 show the bias relative to the target concentration during the years when NDNS samples were being analysed. Filled circles represent HNR results; open circles represent results from other laboratories which use the same method as HNR. DI (Deviation Index) relates to the distribution of results from all laboratories and indicates by how many standard deviations a HNR result differs from the All Laboratory Trimmed Mean. Better performance is indicated by lighter shading.

A small DI (+ or -) indicates close agreement. Mean Running Bias Index Score (MRBIS) is the mean of the 10 most recent bias estimates; results of 0.51 (Year 1), 0.22 (Year 2), -0.44 (Year 3) and 0.10 (Year 4) indicate that there was good overall agreement between HNR results and the target concentrations.


**Figure P.11 External quality controls for ferritin for Year 1 of the NDNS RP**  
(filled circles represent NDNS RP results; open circles represent results obtained by other users of the same analytical method)




**Figure P.12 External quality controls for ferritin for Year 2 of the NDNS RP**  
(filled circles represent NDNS RP results; open circles represent results obtained by other users of the same analytical method)



**Figure P.13 External quality controls for ferritin for Year 3 of the NDNS RP**  
(filled circles represent NDNS RP results; open circles represent results obtained by other users of the same analytical method).



**Figure P.14 External quality controls for ferritin for Year 4 of the NDNS RP (filled circles represent NDNS RP results; open circles represent results obtained by other users of the same analytical method).**



### **P.2.7 Plasma soluble transferrin receptors (sTfR)**

The soluble transferrin receptor (sTfR) assay is an enzyme immunoassay (EIA) based upon the double antibody sandwich method (Ramco Laboratories Inc, Texas, USA). Plasma samples are diluted in buffer and pipetted into microwells pre-coated with a polyclonal antibody to sTfR. Horseradish peroxidase (HRP) conjugated murine monoclonal antibody specific for sTfR is added to the wells and incubated for two hours at room temperature. During this incubation, the sTfR binds to the polyclonal antibodies adsorbed to the wells and the HRP-conjugated second antibodies bind to the captured sTfR. Any unbound sTfR and excess HRP conjugate are removed from the wells by washing. Enzyme substrate (tetramethylbenzidine, TMB) is added to the wells and through the action of HRP forms a blue product. Upon the addition of an acid stop solution the blue product is converted to a yellow colour, the intensity of which is measured in a plate reader set at 450nm. A standard curve is generated by plotting the absorbance versus concentration of the sTfR standards provided in the kit. The concentration of the sTfR in the sample is then determined by comparing the sample's absorbance with the standard curve.

The manufacturers' estimate of limit of detection is 0.07µg/mL. In order to optimise sample ID tracking and to minimise analyst-to analyst variation HNR has automated

this assay using the BEST 2000 liquid handling platform (Launch Diagnostics). Results are not compromised by haemolysis.

#### *P.2.7.1 Quality controls for plasma soluble transferrin receptors*

QC samples (low, high) supplied by the kit manufacturer were run in each batch. Because batch changes for these controls will preclude comparisons over the rolling programme, unassayed human plasma was also included. The controls were assayed at the beginning and end of each batch and therefore these statistics represent a combination of intra- and inter-assay precision.

Results for each run were checked to ensure they fell within the manufacturer's target range. The results in Tables P.27-P.30 indicate good between-batch consistency for sTfR results during Years 1 to 4.

There is no external quality assessment scheme for sTfR measurement.

**Table P.27 Internal quality controls for sTfR for Year 1 of the NDNS RP**

	Kit low control	Kit high control	Dade low control	Dade medium control	Dade high control	Unassayed serum
Mean (µg/ml)	5.24	14.95	2.21	3.47	5.43	8.47
SD (µg/ml)	0.50	1.02	0.33	0.31	0.46	0.93
% CV	9.5	6.8	14.9	8.9	8.5	11.0
N	28	28	25	22	24	28

**Table P.28 Internal quality controls for sTfR for Year 2 of the NDNS RP**

	Kit low control	Kit high control	Dade low control	Dade medium control	Dade high control	Unassayed serum
Mean (µg/ml)	5.0	15.9	2.80	4.41	5.52	8.7
SD (µg/ml)	0.22	1.11	0.16	0.21	0.27	0.42
% CV	4.4	7.0	5.7	4.9	4.9	4.8
N	35	35	30	30	31	35

**Table P.29 Internal quality controls for sTfR for Year 3 of the NDNS RP**

	Kit low control	Kit high control	Kit low control	Kit high control	Kit low control	Kit high control	In-house QA
Mean (µg/ml)	5.03	16.68	4.50	18.26	4.59	20.70	8.05
SD (µg/ml)	0.26	1.42	0.40	1.45	0.49	2.96	0.56
% CV	5.12	8.52	8.81	7.95	10.63	14.31	6.95
N	27	28	26	26	18	18	76

Dade controls were discontinued during the year.

**Table P.30 Internal quality controls for sTfR for Year 4 of the NDNS RP**

	Kit low control	Kit high control	In-house QA
Mean (µg/ml)	4.51	17.22	7.41
SD (µg/ml)	0.42	1.58	0.53
% CV	9.4	9.2	7.2
N	50	50	50

### P.2.8 Plasma vitamin C

This assay is based on the procedure described by Vuilleumier and Keck.<sup>5</sup> Samples are stabilised immediately after separation using an equal volume of 10% metaphosphoric acid.

Ascorbic acid in the sample is converted to dehydroascorbic acid by ascorbate oxidase, followed by coupling of the resulting dehydroascorbate with o-phenylene diamine to form a fluorescent derivative quinoxaline. The formation of quinoxaline is linearly related to the amount of vitamin C in the sample. The assay was performed on the BMG Labtech FLUOstar OPTIMA plate reader, which measures the fluorescence.

*P.2.8.1 Internal quality controls for plasma vitamin C*

QC samples were made in-house by spiking ascorbic acid-depleted plasma. The results in Tables P.31-P.34 indicate good between-batch consistency for vitamin C (ascorbic acid) measurements during Years 1 to 4.

**Table P.31 Internal quality controls for vitamin C for Year 1 of the NDNS RP**

Vitamin C	$\mu\text{mol/L}$	
	QC2	QC3
Mean	28.0	51.0
SD	2.8	4.5
% CV	11.1	9.5
N	189	188

**Table P.32 Internal quality controls for vitamin C for Year 2 of the NDNS RP**

Vitamin C	$\mu\text{mol/L}$	
	QC 2	QC 3
Mean	28.0	51.0
SD	3.8	6.2
% CV	13.4	12.0
N	80	80

**Table P.33 Internal quality controls for vitamin C for Year 3 of the NDNS RP**

Vitamin C	$\mu\text{mol/L}$	
	QC2	QC3
mean ( $\mu\text{mol/L}$ )	28.1	52.6
sd ( $\mu\text{mol/L}$ )	2.5	2.9
cv (%)	9.0	5.6
N	68	68




**Table P.34 Internal quality controls for vitamin C for Year 4  
of the NDNS RP**

Vitamin C	$\mu\text{mol/L}$	
	QC2	QC3
mean ( $\mu\text{mol/L}$ )	24.9	51.8
sd ( $\mu\text{mol/L}$ )	1.6	2.3
cv (%)	6.6	4.5
N	78	78


*P.2.8.2 External quality controls for vitamin C*

HNR subscribes to the NIST (National Institute of Standards and Technology) EQAS for vitamin C. Samples were distributed quarterly and results were always within the target range. Results are quoted by NIST in terms of agreement with the “interlaboratory consensus” which is validated against Standard Reference Material 970. HNR results are in close agreement with this validated “interlaboratory consensus” indicating accuracy with respect to the Standard Reference Material.


**Figure P.15 External quality controls for vitamin C for Year 1 of the NDNS RP. Comparison of Measurements to “Interlaboratory Consensus” Values**




**Figure P.16 External quality controls for vitamin C for Year 2 of the NDNS RP. Comparison of Measurements to “Interlaboratory Consensus Values”**



**Figure P.17 External quality controls for vitamin C for Year 3 of the NDNS RP. Comparison of Measurements to “Interlaboratory Consensus”**



**Figure P.18 External quality controls for vitamin C for Year 4 of the NDNS RP.**  
**Comparison of Measurements to “Interlaboratory Consensus”**





### **P.2.9 Erythrocyte transketolase activation coefficient (ETKAC) for thiamin status**

This assay is based on that of Vuilleumier *et al*<sup>6</sup> and depends on the coupling of pyridine nucleotide oxidation to glycerol phosphate dehydrogenase (GDH) (NADH linked), which produces glycerol-3-phosphate after the transketolase-catalysed conversion of ribose-5-phosphate. The rate of oxidation of NADH is monitored at 340nm, on the Multiskan FC plate-reader, in which instrument temperature equivalence across the plate can be achieved. Thiamin status is assessed using the activation coefficient, which is the ratio of cofactor-stimulated activity to the basal activity without any added cofactor.

This method is identical in principle with its predecessor on the Cobas Fara platform. An analysis of bias between the results determined on the two platforms was performed ahead of the NDNS RP.

There are no available sources of erythrocytes with known ETKAC; therefore unassayed material was prepared in-house. Erythrocytes from National Blood Transfusion Service (NBTS) or commercial sources were washed to remove the buffy coat and lysed by threefold dilution with water. This lysate was stored at -80°C in single-use aliquots. The lysate was stored and assayed both neat and further diluted x2 with water. No source of thiamin deficient erythrocytes has been identified with which to prepare a lysate giving high ETKAC; similarly none of the participant's samples had resulted in an ETKAC in the deficient range (greater than 1.25).

#### ***P.2.9.1 Quality control results for ETKAC***

Descriptive statistics in Tables P.35-P.38 for internal QC's indicate good batch-to-batch consistency of ETKAC results during Years 1 to 4.

There are no external Quality Assurance or QC schemes available for ETKAC.

**Table P.35 Internal quality controls for ETKAC for Year 1 of the NDNS RP**

Control ID	Scipac B	UK NBTS neat*	UK NBTS diluted x2*	UK NBTS neat**	UK NBTS diluted x2**
Mean	1.06	1.08	1.07	1.05	1.05
SD	0.04	0.03	0.04	0.04	0.05
% CV	3.6	2.3	3.8	3.6	4.7
N	35	28	27	15	15

\* old QC material, now finished

\*\* new QC material being run in parallel

**Table P.36 Internal quality controls for ETKAC for Year 2 of the NDNS RP**

Control ID	Scipac B	UK NBTS neat	UK NBTS, diluted x 2
Mean	1.07	1.02	1.03
SD	0.06	0.07	0.04
% CV	5.4	6.8	3.6
N	29	29	29

**Table P.37 Internal quality controls for ETKAC for Year 3 of the NDNS RP**

Control ID	Scipac B	UK NBTS neat	UK NBTS, diluted x 2	Scipac A	Scipac C	Scipac A diluted x2
Mean	1.05	1.03	1.06	1.11	1.08	1.11
SD	0.04	0.03	0.03	0.07	0.03	0.07
% CV	3.66	2.86	2.37	6.20	3.12	6.12
N	22	30	30	26	26	25

**Table P.38 Internal quality controls for ETKAC for Year 4 of the NDNS RP**

Control ID	Scipac A	Scipac C	Scipac A diluted x2	Scipac P	Scipac Q
mean	1.08	1.09	1.11	1.05	1.15
sd	0.06	0.04	0.05	0.04	0.05
cv	5.79	3.30	4.86	3.71	4.44
n	37	38	30	26	26

### **P.2.10 Erythrocyte glutathione reductase activation coefficient (EGRAC) for riboflavin status**

This assay was developed from the original manual technique developed by Glatzle *et al*<sup>7</sup> and was adapted to the 'in-house' method using a Cobas Fara centrifugal analyser, which in turn has been modified to an assay carried out on microplates and read on a Thermo iEMS plate reader. The ratio of flavin adenine dinucleotide (FAD) stimulated to unstimulated activity is the EGRAC and is a measure of riboflavin status. The method is a kinetic test with decreasing absorbance and the preincubation with FAD is carried out for a relatively long period, 30 minutes at 37°C, in order to ensure full reactivation of apo-enzyme. The assay is conducted at a low final concentration of FAD (1.5µM), which is necessary to eliminate activation coefficients (ratios) <1.0; this can result from enzyme inhibition by FAD, or its breakdown products, which may occur if the final concentration of FAD is too high.

The assay is in principle identical to its predecessor which used the Cobas Fara. A comparison of results obtained on the two platforms was performed using NDNS RP Year 1 quarter 1 samples, which showed good agreement.

#### *P.2.10.1 Quality controls for EGRAC*

There is no control with known EGRAC available, therefore washed erythrocytes were prepared in-house, aliquoted for single use and stored at -80°C. In addition to the native samples a saturated control was made by incubation with FAD before aliquoting. These three controls were run on each assay plate. There is no external quality assessment scheme available for EGRAC.

##### *P.2.10.1.1 Internal quality control results during Years 1 to 4*

Descriptive statistics in Tables P.39-P.42 for internal QC's indicate good batch-to-batch consistency of EGRAC results during Years 1 to 4.

**Table P.39 Internal quality controls for EGRAC for Year 1 of the NDNS RP**

Control ID	A	C	X
Mean	2.14	1.52	0.99
SD	0.16	0.07	0.02
% CV	7.3	4.9	1.8
N	30	32	32

**Table P.40 Internal quality controls for EGRAC for Year 2 of the NDNS RP**

Control ID	A	C	X
Mean	2.28	1.60	0.99
SD	0.15	0.06	0.02
% CV	6.4	3.6	2.3
N	33	34	34

**Table P.41 Internal quality controls for EGRAC for Year 3 of the NDNS RP**

Control ID	A	C	X
Mean	2.27	1.63	1.00
SD	0.10	0.03	0.02
% CV	4.23	2.14	1.95
N	71	69	72

**Table P.42 Internal quality controls for EGRAC for Year 4 of the NDNS RP**

Control ID	A	C	X
Mean	2.30	1.61	0.99
SD	0.08	0.03	0.01
% CV	3.60	2.16	1.44
N	37	40	40

### **P.2.11 Plasma vitamin B<sub>6</sub> (PLP and PA)**

A reverse-phase high performance liquid chromatography (HPLC) method with post column derivatisation and fluorimetric detection was used to determine pyridoxal-5-phosphate (PLP) and 4-pyridoxic acid (PA) in plasma.<sup>8</sup>

#### *P.2.11.1 Quality controls for vitamin B<sub>6</sub>*

QC was achieved through internal procedures. QC material was produced by spiking human plasma with aqueous solutions of PLP and PA. The final QC concentration was designed to match typical mid-range human samples. The QC material was spiked so that the additional aqueous content represented only 0.02% of the total medium. Duplicate analysis of the QC material was performed with each analytical run, and the mean recovery of added PLP and PA was calculated for each run. When the mean percentage recovery was outside of the range 95 to 105% of nominal the analytical results for that run were corrected accordingly.

There were no external quality schemes for the vitamin B<sub>6</sub> HPLC method.



#### *P.2.11.1.1 Internal quality controls for vitamin B<sub>6</sub>*

The basal and spiked plasma used to calculate analytical recovery for each assay were also used to determine assay precision, where concentrations were appropriate. However for Year 1, Year 2 and the beginning of Year 3 the unspiked plasma contained a concentration of PLP and PA close to the limit of quantitation and too low for determining precision; any samples containing similarly low concentrations of PLP and PA were reassayed at double volume to permit quantitation. Therefore this unspiked plasma cannot be used to determine precision and only the spiked QC results are available for this time period.

QC results for unspiked plasma have been corrected for analytical recovery where this correction was also performed for the unknown samples in that batch.

QC results for spiked plasma have not been so corrected; as the spike recovery was used to define the correction factor (if any) for that batch, using this factor to correct the concentration measured in the same spiked control would be inappropriate.

Therefore the imprecision shown for spiked controls is likely to overestimate the imprecision applicable to measured concentrations of unknown samples.

The good agreement between the obtained values for PLP and PA in the quality control and the expected values in Tables P.43-P.44 indicate a quantitative recovery of vitamin B<sub>6</sub> in this assay.

**Table P.43 Internal quality controls for PLP and PA (un-spiked plasma) for Years 3 (part) and 4 of the NDNS RP**

<b>PLP</b>	<b>Year 3 (part)</b>	<b>Year 4</b>
Mean (nmol/L)	11.0	10.5
SD	2.0	0.9
% CV	18.4	8.9
n	24	48
<b>PA</b>	<b>Year 3 (part)</b>	<b>Year 4</b>
Mean (nmol/L)	34.8	34.3
SD	1.8	2.0
% CV	5.0	5.9
n	24	48

(no data available for earlier assays, see above)

**Table P.44 Internal quality controls for PLP and PA (spiked plasma) for Years 1, 2, 3 and 4 of the NDNS RP**

<b>PLP</b>	<b>Year 1</b>	<b>Year 2</b>	<b>Year 3</b>	<b>Year 4</b>
Mean (nmol/L)	43.9	44.1	45.9	44.9
SD	2.2	3.0	4.3	2.1
% CV	5.1	6.8	9.4	4.8
n	32	36	36	48
<b>PA</b>	<b>Year 1</b>	<b>Year 2</b>	<b>Year 3</b>	<b>Year 4</b>
Mean (nmol/L)	52.0	52.3	53.8	54.9
SD	2.1	1.9	3.1	3.3
% CV	4.1	3.7	5.8	6.1
n	32	35	36	48

Note that the expected PLP concentration of the spiked plasma was 43nmol/L (the sum of the basal level in the plasma plus the spike concentration). The expected PA concentration of the spiked plasma was 51nmol/L (the sum of the basal level in the plasma plus the spike concentration). The table above indicates consistent accuracy.

### **P.2.12 Plasma total homocysteine**

This assay was performed using the Siemens BN ProSpec® system which uses particle-enhanced immunonephelometry for the quantitative determination of homocysteine in heparinised human plasma. In the competitive assay, bound homocysteine in the sample is reduced to free homocysteine by the action of dithiothreitol, and then converted enzymatically to S-adenosyl-homocysteine (SAH) in the next step. Conjugated S-adenosylcysteine (SAC), added at the onset of the reaction, competes with the SAH in the sample for bonding by anti-SAH antibodies bound to polystyrene particles. In the presence of SAH, there is either no aggregation or a weaker aggregation of particles. In the absence of SAH in the sample, an aggregation of the polystyrene particles by the conjugated SAC occurs. The higher the SAH content of the reaction mixture, the smaller the scattered light signal. The concentration is determined by comparison with a calibrant of known concentration.

#### *P.2.12.1 Quality controls for plasma total homocysteine*

QC was achieved through internal and external procedures. Control serum was obtained commercially containing low medium and high concentrations of homocysteine and was included in each run. Results were checked to ensure they fell within the manufacturer's target range. Because the manufacturer's "acceptable" results range was very wide, HNR determined more stringent site-specific precision requirements within the manufacturer's published range and QC results for each analytical run were judged against these more demanding criteria, using JMPIN QC software.

In order to confirm analytical accuracy, HNR participated in an international external quality assessment scheme for homocysteine. Four samples were distributed by the scheme per year. HNR results were rated "within consensus" relative to the overall spread of results, indicating acceptable conformity of HNR's reported homocysteine results to the inter-laboratory consensus concentration.

*P.2.12.1.1 Internal quality controls for plasma total homocysteine*

The results in Tables P.45-P.48 indicate good between-batch consistency for homocysteine results during Years 1 to 4.

**Table P.45 Internal quality controls for homocysteine for Year 1 of the NDNS RP**

Year 1	Low		Medium		High	
Mean (µmol/l)	7.2	12.2	11.1	12.1	23.8	24.4
SD (µmol/l)	0.6	0.9	0.8	0.9	2.2	1.6
% CV	7.8	7.2	7.5	7.5	9.1	6.6
N	19	30	20	30	18	23

**Table P.46 Internal quality controls for homocysteine for Year 2 of the NDNS RP**

Year 2	Low	Medium	High
Mean (µmol/l)	7.6	11.9	24.3
SD (µmol/l)	0.5	1.0	1.5
% CV	6.9	8.8	6.0
N	11	12	13

**Table P.47 Internal quality controls for homocysteine for Year 3 of the NDNS RP**

Year 3	Low			Medium		High		
Mean (µmol/l)	7.2	6.5	7.0	10.8	12.0	25.2	23.8	24.1
SD (µmol/l)	0.8	0.5	0.7	1.1	1.1	2.0	1.7	2.6
% CV	11.0	7.5	9.6	9.7	8.8	7.8	7.2	10.7
N	11	7	12	9	10	11	7	12

**Table P.48 Internal quality controls for homocysteine for Year 4 of the NDNS RP**

Year 4	Low			Medium			High		
Mean (µmol/l)	7.7	8.5	7.0	12.1	11.6	12.9	26.1	25.0	24.1
SD (µmol/l)	0.8	0.8	0.6	1.6	1.6	1.2	2.4	3.4	1.7
% CV	10.0	8.9	8.5	13.5	13.6	9.0	9.1	13.7	6.9
N	3	8	16	3	13	11	3	13	11

### **P.2.13 Plasma retinol, retinyl palmitate, $\alpha$ - and $\gamma$ -tocopherol, and individual carotenoids**

Fat soluble micronutrients were determined by HPLC coupled to a photodiode array detector, capable of multi-wavelength detection. The analytical method used was derived from Thurnham *et al.*<sup>9</sup> Samples were assayed as singletons. Plasma concentrations of vitamin A (retinol), retinyl palmitate,  $\alpha$ -, and  $\gamma$ -tocopherol, and seven carotenoids ( $\alpha$ - and  $\beta$ -carotene,  $\alpha$ - and  $\beta$ -cryptoxanthin, lycopene and lutein and zeaxanthin [xanthophyll]) were determined. An internal standard of tocopherol acetate was used to monitor losses during the extraction process and to account for any changes in volumes.

The analytical method in the current survey was essentially the same as that used in all previous NDNS surveys. However it should be noted that differences in calibration techniques and in the application of extraction efficiency corrections may mean that it is not possible to directly compare the results of this survey with previous NDNS surveys.

#### ***P.2.13.1 Quality controls for plasma retinol, retinyl palmitate, $\alpha$ - and $\gamma$ -tocopherol and individual carotenoids***

The nature of these assays, which measure ten analytes in a single HPLC run, means that achieving good accuracy and precision are a greater challenge than in a single-analyte assay. Therefore in order to get the best results possible more quality processes are needed than for the other assays.

Heparinised human plasma from a commercial source (e.g. Seralab International, UK) was run in duplicate for every batch of samples. To check the extraction efficiency of the method a sample of this plasma was spiked with a known concentration of each fat soluble vitamin analyte. This spiking was performed freshly, immediately before sample preparation for each analytical batch.

Following extraction, the concentration of each fat soluble vitamin component was determined (duplicates) in both un-spiked and fortified plasma and the percentage recovery for each spike determined from the mean concentrations, by subtraction. Participant results in any batch where the extraction efficiency was different from 100% were corrected to allow for this.

Acceptable extraction efficiency was based on ranges established in this laboratory.

**Table P.49 Extraction efficiencies for fat soluble vitamins (FSV) assays for Years 1, 2, 3 and 4 of the NDNS RP**

Extraction Efficiencies - FSV assays (%)					
Analyte		Year 1 n=12	Year 2 n=16	Year 3 n=15	Year 4 n=18
retinol	Mean	104	93	108	95
	sd	7	16	13	10
retinyl palmitate	Mean	98	84	92	78
	sd	16	17	7	7
$\alpha$ - tocopherol	Mean	103	96	92	102
	sd	7	19	8	12
$\gamma$ -tocopherol	Mean	105	90	93	94
	sd	7	14	9	12
Lutein	Mean	73	88	104	96
	sd	12	19	14	9
$\alpha$ -cryptoxanthin	Mean	96	83	84	78
	sd	12	16	6	10
$\beta$ -cryptoxanthin	Mean	85	84	84	91
	sd	8	7	5	10
lycopene	Mean	72	99	78	83
	sd	12	21	23	8
$\alpha$ -carotene	Mean	75	83	69	63
	sd	5	20	11	5
$\beta$ -carotene	Mean	65	78	69	66
	sd	8	12	10	6

The measured concentrations in the unspiked and spiked samples for each assay have retrospectively been compared to give an approximate indication of assay imprecision for each year, where the concentrations are high enough for this to be valid. The difficulties inherent in spiking plasma with analytes which are not water-

soluble precluded spiking in bulk and freezing aliquots for multiple assays, and therefore conventional assay imprecision data are not available.

Participation in studies conducted by National Institute of Standards and Technology (NIST), CDC VITAL-External Quality Assurance (CDC VITAL EQA) and UKNEQAS allowed inter-laboratory comparison of results. HNR also participated in a twice yearly “round robin” with both NIST and VITAL EQA. At the start of the NDNS RP NEQAS samples were received bi-monthly; the frequency was later increased to monthly samples. The following carotenoids:  $\alpha$ -carotene,  $\beta$ -cryptoxanthin, lutein/zeaxanthin and lycopene are measured by five laboratories or fewer and therefore the returns from these schemes are only useful for indicating whether each laboratory’s results are broadly similar to those obtained by other participating laboratories. In such cases the charts are not presented in this report.

*P.2.13.1.1 Internal quality controls for plasma retinol, retinyl palmitate,  $\alpha$ - and  $\gamma$ -tocopherol and individual carotenoids*

The Fat Soluble Vitamin (FSV) results for Years 1 to 4 were reported as plasma retinol, retinyl palmitate,  $\alpha$ - and  $\gamma$ -tocopherol and individual carotenoids. (Lutein and zeaxanthin co-elute and therefore are measured as a sum.)

Tables P.50-P.57 show, for each analyte, the precision of measurement of unspiked plasma and of the individually spiked plasma samples used for recovery efficiency calculation for each batch. These are presented in addition to the precision of spike recovery (Tables P.58-P.61) which has been included in previous NDNS RP reports.

The unspiked and spiked controls were selected and included in each batch for accuracy assessment and have retrospectively been tabulated for the purposes of precision monitoring. In some cases the concentrations of unspiked plasma are extremely low and are not suitable for this purpose.

Control concentrations are “as measured”; they have not been corrected for extraction efficiency. They therefore represent an overestimate of the imprecision of FSV concentrations in NDNS RP samples. Also, as mentioned above, the *de novo*



preparation of the spiked samples individually for each assay will inevitably have contributed to the overall imprecision.

The batch of unspiked plasma was changed after analysis of the Year 1 samples.

**Table P.50 Unspiked plasma results for plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 1 of the NDNS RP**

	<b>Retinol (<math>\mu\text{mol/L}</math>)</b>	<b>Retinyl palmitate (<math>\mu\text{mol/L}</math>)<sup>1</sup></b>	<b><math>\alpha</math>-tocopherol (<math>\mu\text{mol/L}</math>)</b>	<b><math>\gamma</math>-tocopherol (<math>\mu\text{mol/L}</math>)</b>	<b><math>\alpha</math>-carotene (<math>\mu\text{mol/L}</math>)</b>
Mean	1.41	-	6.05	3.35	
SD	0.06	-	0.30	0.18	
% CV	4.5	-	4.9	5.4	
N	16	-	16	16	

<sup>1</sup> No value is given for retinyl palmitate or  $\alpha$ carotene in unspiked plasma because the concentrations are too low for reliable quantitation, and are lower than the 2.5<sup>th</sup> percentile of NDNS RP results.

	<b><math>\beta</math>-carotene (<math>\mu\text{mol/L}</math>)</b>	<b><math>\alpha</math>-cryptoxanthin (<math>\mu\text{mol/L}</math>)<sup>1</sup></b>	<b><math>\beta</math>- cryptoxanthin (<math>\mu\text{mol/L}</math>)</b>	<b>Lycopene (<math>\mu\text{mol/L}</math>)</b>	<b>Lutein (<math>\mu\text{mol/L}</math>)</b>
Mean	0.182*	-	0.048*	0.163*	0.22
SD	0.03	-	0.01	0.03	0.02
% CV	14.3	-	23.9	21.3	8.7
N	16	-	16	16	16

<sup>1</sup> No value is given for  $\alpha$ -cryptoxanthin in unspiked plasma because the concentrations are too low for reliable quantitation, and are lower than the 2.5<sup>th</sup> percentile of NDNS RP results.

\*concentration similar to the 2.5<sup>th</sup> percentile of NDNS RP results.

**Table P.51     Unspiked plasma results for plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 2 of the NDNS RP (new QC plasma batch)**

	<b>Retinol (<math>\mu\text{mol/L}</math>)</b>	<b>Retinyl palmitate (<math>\mu\text{mol/L}</math>)<sup>1</sup></b>	<b><math>\alpha</math>-tocopherol (<math>\mu\text{mol/L}</math>)</b>	<b><math>\gamma</math>-tocopherol (<math>\mu\text{mol/L}</math>)</b>	<b><math>\alpha</math>-carotene (<math>\mu\text{mol/L}</math>)</b>
Mean	1.44	-	20.57	3.62	0.08*
SD	0.14	-	1.69	0.76	0.02
% CV	9.7	-	8.2	20.9	23.3
N	9	-	8	8	7

<sup>1</sup> No value is given for retinyl palmitate in unspiked plasma because the concentrations are too low for reliable quantitation, and are lower than the 2.5<sup>th</sup> percentile of NDNS RP results.

	<b><math>\beta</math>-carotene (<math>\mu\text{mol/L}</math>)</b>	<b><math>\alpha</math>-cryptoxanthin (<math>\mu\text{mol/L}</math>)<sup>1</sup></b>	<b><math>\beta</math>- cryptoxanthin (<math>\mu\text{mol/L}</math>)</b>	<b>Lycopene (<math>\mu\text{mol/L}</math>)</b>	<b>Lutein (<math>\mu\text{mol/L}</math>)</b>
Mean	0.27*	-	0.09	0.46	0.30
SD	0.09	-	0.02	0.07	0.03
% CV	33.1	-	17.8	16.1	8.6
N	7	-	7	7	7

<sup>1</sup> No value is given for  $\alpha$ -cryptoxanthin in unspiked plasma because the concentrations are too low for reliable quantitation, and are lower than the 2.5<sup>th</sup> percentile of NDNS RP results.

\*concentration similar to the 2.5<sup>th</sup> percentile of NDNS RP results

**Table P.52    Unspiked Plasma results for plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 3 of the NDNS RP**

	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ ) <sup>1</sup>	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	1.57	-	17.1	4.82	0.05
SD	0.19	-	2.25	1.42	0.02
% CV	12.2	-	13.1	29.4	47.4
N	15	-	15	15	15

<sup>1</sup> No value is given for retinyl palmitate in unspiked plasma because the concentrations are too low for reliable quantitation, and are lower than the 2.5<sup>th</sup> percentile of NDNS RP results.

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ ) <sup>1</sup>	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean		-	0.06	0.22*	0.23*
SD		-	0.01	0.12	0.07
% CV		-	21.0	53.4	32.3
N		-	15	15	15

<sup>1</sup> No value is given for  $\alpha$ -cryptoxanthin or  $\beta$ -carotene in unspiked plasma because the concentrations are too low for reliable quantitation, and are lower than the 2.5<sup>th</sup> percentile of NDNS RP results.

\* concentration similar to the 2.5<sup>th</sup> percentile of NDNS RP results

**Table P.53    Unspiked Plasma results for plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 4 of the NDNS RP**

	<b>Retinol (<math>\mu\text{mol/L}</math>)</b>	<b>Retinyl palmitate (<math>\mu\text{mol/L}</math>)<sup>1</sup></b>	<b><math>\alpha</math>-tocopherol (<math>\mu\text{mol/L}</math>)</b>	<b><math>\gamma</math>-tocopherol (<math>\mu\text{mol/L}</math>)</b>	<b><math>\alpha</math>-carotene (<math>\mu\text{mol/L}</math>)</b>
Mean	1.36	-	19.1	3.31	
SD	0.11	-	1.31	0.29	
% CV	8.1	-	6.9	8.6	
N	18	-	18	18	

<sup>1</sup> No value is given for retinyl palmitate or  $\alpha$ -carotene in unspiked plasma because the concentrations are too low for reliable quantitation, and are lower than the 2.5<sup>th</sup> percentile of NDNS RP results.

	<b><math>\beta</math>-carotene (<math>\mu\text{mol/L}</math>)</b>	<b><math>\alpha</math>-cryptoxanthin (<math>\mu\text{mol/L}</math>)<sup>1</sup></b>	<b><math>\beta</math>-cryptoxanthin (<math>\mu\text{mol/L}</math>)</b>	<b>Lycopene (<math>\mu\text{mol/L}</math>)</b>	<b>Lutein (<math>\mu\text{mol/L}</math>)</b>
Mean		-	0.034	0.18*	0.15*
SD		-	0.02	0.08	0.03
% CV		-	49.6	44.9	21.0
N		-	18	18	18

<sup>1</sup> No value is given for  $\beta$ -carotene or  $\alpha$ -cryptoxanthin in unspiked plasma because the concentrations are too low for reliable quantitation, and are lower than the 2.5<sup>th</sup> percentile of NDNS RP results.

\*concentration similar to the 2.5<sup>th</sup> percentile of NDNS RP results

**Table P.54 Precision of concentration measurement in individually-spiked recovery samples - plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 1 of the NDNS RP**

	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ )	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	5.08	0.266	32.7	8.58	0.171
SD	0.21	0.066	1.8	.81	0.019
% CV	4.2	24.7	5.6	9.5	11.1
N	31	31	31	31	32

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ )	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean	0.653	0.135	0.157	0.463	0.447
SD	0.107	0.024	0.024	0.212	0.048
% CV	16.4	17.7	15.5	45.9	10.7
N	32	32	32	32	32

**Table P.55 Precision of concentration measurement in individually-spiked recovery samples - plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 2 of the NDNS RP**

NB This is a different plasma from that used in Year 1

	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ )	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	3.95	0.489	37.2	7.84	0.245
SD	0.28	0.036	1.85	0.64	0.048
% CV	7.2	7.3	5.0	8.2	19.7
N	18	16	15	16	14

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ )	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean	0.781781	0.158	0.208	0.85	0.604
SD	0.139	0.028	0.019	0.15	0.069
% CV	17.8	17.7	9.1	17.6	11.3
N	14	14	14	14	14

**Table P.56 Precision of concentration measurement in individually-spiked recovery samples - plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 3 of the NDNS RP**

	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ )	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	4.92	0.592	34.4	9.19	0.177
SD	0.80	0.072	3.18	1.43	0.039
% CV	16.2	12.1	9.2	15.5	22
N	25	28	28	28	27

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ )	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean	0.676	0.143	0.184	0.505	0.626
SD	0.132	0.02	0.019	0.177	0.104
% CV	19.6	13.8	10.2	35.1	16.7
N	30	30	30	30	30

**Table P.57 Precision of concentration measurement in individually-spiked recovery samples - plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 4 of the NDNS RP**

	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ )	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	4.28	0.504	36.7	7.81	0.133
SD	0.53	0.058	3.09	0.754	0.019
% CV	12.5	11.5	8.4	9.7	13.9
N	36	36	36	36	36

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ )	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean	0.604	0.118	0.166	0.495	0.491
SD	0.088	0.022	0.025	0.084	0.058
% CV	14.5	18.2	14.8	16.9	11.9
N	36	35	36	36	36

**Table P.58 Precision of recovered spike for plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 1 of the NDNS RP**

	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ )	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	3.67	0.28	20.02	5.69	0.14
SD	0.17	0.06	0.75	0.26	0.01
% CV	4.7	19.7	3.8	4.5	6.6
N	16	11	9	9	13

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ )	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean	0.50	0.13	0.12	0.26	0.24
SD	0.11	0.02	0.02	0.05	0.04
% CV	22.0	15.4	14.1	18.8	18.2
N	15	15	14	13	14

**Table P.59 Precision of recovered spike for plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 2 of the NDNS RP**

	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ )	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	2.50	0.48	16.64	4.11	0.15
SD	0.05	0.02	0.85	0.17	0.04
% CV	2.0	4.6	5.1	4.2	23.7
N	8	8	6	6	15

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ )	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean	0.59	0.12	0.12	0.37	0.31
SD	0.07	0.03	0.01	0.07	0.05
% CV	12.4	22.9	8.9	17.9	16.1
N	15	13	15	15	15



**Table P.60 Precision of recovered spike for plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 3 of the NDNS RP**

	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ )	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	3.48	0.60	16.74	4.6	0.13
SD	0.49	0.06	1.66	0.45	0.02
% CV	14.1	9.2	9.9	9.7	17.8
N	12	13	13	13	14

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ )	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean	0.5	0.12	0.12	0.28	0.39
SD	0.07	0.01	0.01	0.08	0.10
% CV	14.1	11.0	6.8	28.7	25.4
N	14	14	14	14	14

**Table P.61 Precision of recovered spike for plasma retinol, plasma retinyl palmitate,  $\alpha$ - and  $\gamma$ - tocopherol and individual carotenoids for Year 4 of the NDNS RP**


	Retinol ( $\mu\text{mol/L}$ )	Retinyl palmitate ( $\mu\text{mol/L}$ )	$\alpha$ -tocopherol ( $\mu\text{mol/L}$ )	$\gamma$ -tocopherol ( $\mu\text{mol/L}$ )	$\alpha$ -carotene ( $\mu\text{mol/L}$ )
Mean	2.92	0.500	17.60	4.51	0.12
SD	0.38	0.05	2.12	0.55	0.01
% CV	13.1	9.4	12.0	12.2	8.0
n	18	18	18	18	18

	$\beta$ -carotene ( $\mu\text{mol/L}$ )	$\alpha$ -cryptoxanthin ( $\mu\text{mol/L}$ )	$\beta$ -cryptoxanthin ( $\mu\text{mol/L}$ )	Lycopene ( $\mu\text{mol/L}$ )	Lutein ( $\mu\text{mol/L}$ )
Mean	0.50	0.11	0.13	0.31	0.34
SD	0.05	0.01	0.01	0.04	0.03
% CV	9.6	12.9	10.5	12.1	9.6
n	18	18	18	18	18

*P.2.13.1.2 External quality controls for plasma retinol, retinyl palmitate,  $\alpha$ - and  $\gamma$ -tocopherol and individual carotenoids*


Figure P.13 shows bias scores for UKNEQAS returns during the period covering Years 1 to 4 of the NDNS RP. Percentage bias was calculated as (result-target)/target\*100 and was calculated as a rolling average by UKNEQAS. The results from the external quality schemes shown in Figures P.19.-P.24 suggest that HNR is typically within the range for each fat soluble vitamin analyte. For the purpose of this report retinol and  $\alpha$ - tocopherol are represented by the vitamin A and vitamin E UKNEQAS returns respectively. Data are only presented where the number of participating laboratories exceeds 10; this excludes carotenoids other than  $\beta$ -carotene.

**Figure P.19 NDNS RP Years 1 and 2 NEQAS bias score data for retinol (40 labs in scheme)**




Distribution 108 to 111 covers NDNS Year 1; distribution 112 to 116 covers NDNS Year 2

**Figure P.20 NDNS RP Years 1 and 2 NEQAS bias score data for vitamin E (alpha-tocopherol) (40 labs in scheme)**




Distribution 108 to 111 covers NDNS Year 1; distribution 112 to 116 covers NDNS RP Year 2

**Figure P.21 NDNS RP Years 1 and 2 NEQAS bias score data for beta-carotene (19 labs in scheme)**




Distribution 108 to 111 covers NDNS Year 1; distribution 112 to 116 covers NDNS year 2

**Figure P.22 NDNS RP Years 3 and 4 NEQAS bias score data for retinol (45 labs in scheme)**




Distribution 119 to 121 covers NDNS Year 3; distribution 128 to 130 covers NDNS Year 4

**Figure P.23 NDNS RP Years 3 and 4 NEQAS bias score data for vitamin E (alpha-tocopherol) (45 labs in scheme)**



Distribution 119 to 121 covers NDNS Year 3; distribution 128 to 130 covers NDNS Year 4

**Figure P.24 NDNS RP Years 3 and 4 NEQAS bias score data for beta-carotene (18 labs in scheme)**



Distribution 119 to 121 covers NDNS Year 3; distribution 128 to 130 covers NDNS Year 4


#### **P.2.14 Plasma 25-hydroxyvitamin D (25-OHD)**

The DiaSorin Liaison method for quantitative determination of 25-OHD is a direct, competitive chemiluminescence immunoassay (CLIA). A specific antibody to vitamin D is used for coating magnetic particles (solid phase), and vitamin D is linked to an isoluminol derivative. During the incubation, 25-OHD is dissociated from its binding protein, and competes with labeled vitamin D for binding sites on the antibody. After the incubation, the unbound material is removed with a wash cycle. Subsequently, the starter reagents are added and a flash chemiluminescent reaction is initiated. The light signal is measured by a photomultiplier as relative light units (RLU) and is inversely proportional to the concentration of 25-OHD present in calibrators, controls, or samples.

The DiaSorin radio-immunoassay method was used in previous NDNS<sup>10,11,12,13</sup> to measure 25-OHD in plasma. A comparison study was carried out between the DiaSorin RIA method and the DiaSorin Liaison method; this showed good agreement.

Samples for Year 1 to Year 3 and early months of Year 4 were analysed in lithium heparin plasma, using DiaSorin Liaison reagents prior to the company's reformulation of the reagent kit during late 2011. The remainder of the Year 4 samples were analysed in serum using the reformulated Diasorin kits which are accredited for serum only, not plasma. A comparison of over 100 samples conducted at HNR indicated that there is no bias between the results given by the two versions of the Diasorin Liaison method, as shown in Figure P.25.

**Figure P.25 Comparison of 25-OHD measured in serum (new formulation kits) vs plasma (old formulation kits)**



#### *P.2.14.1 Quality controls for 25-OHD*

Internal QCs were run with every batch, and HNR NBA also subscribed to the DEQAS external quality assessment scheme.

#### *P.2.14.1.1 Internal quality controls for 25-OHD*

Manufacturer's controls were run with each kit. These allow an instant assessment of whether the results obtained for respondents' samples are within limits. However as each batch of these is only issued for a short period they do not assess longer-term stability of the assay. For Year 1, the numbers for each lot were too small to be meaningful and so a Lyphochek control was also run at intervals within each run to check for assay drift and consistency over a longer period (Table P.62). For Years 2, 3 and 4 more data were available for manufacturer controls and these are also included in Tables P.63-P.65.

**Table P.62 Internal quality controls for 25-OHD for Year 1 of the NDNS RP**

	Lyphochek (nmol/L)
Mean	48.8
SD	6.1
%CV	12.6

**Table P.63 Internal quality controls for 25-OHD for Year 2 of the NDNS RP**

	Control 1 (123521D) (nmol/L)	Control 2 (123521D) (nmol/L)	Lyphochek (nmol/L)
Mean	40.1	134	51.4
SD	3.8	10.3	6.0
% CV	9.4	7.7	11.7
N	23	22	21

**Table P.64 Internal quality controls for 25-OHD for Year 3 of the NDNS RP**

Manufacturer's controls: (nmol/L)							Lyphochek (nmol/L)
Mean	41.6	146.2	41.0	133.2	40.6	130.4	55.9
SD	3.4	7.8	3.2	9.3	4.4	8.8	6.6
% CV	8.3	5.3	7.7	7.0	10.9	6.7	11.9
N	16	16	23	23	18	18	42

**Table P.65 Internal quality controls for 25-OHD for Year 4 of the NDNS RP**

Manufacturer's controls: (nmol/L)									Lyphochek (nmol/L)
Mean	40.9	127	31.1	106.3	46	147	41.7	130.4	54.1
SD	4.2	8.6	3.0	4.9	2.7	5.9	1.9	3.6	3.9
% CV	10.1	8.5	9.6	4.6	6	4.0	4.6	2.8	7.2
N	10	10	9	9	9	9	11	11	26


#### *P.2.14.1.2 External quality controls for 25-OHD*

HNR subscribed to the DEQAS external quality assessment scheme and the NBA laboratory's performance was assessed by the scheme organisers as meeting the performance target set by the DEQAS Advisory Panel (i.e. 80% or more of results were within  $\pm 30\%$  of the All Laboratory Trimmed Mean). DEQAS do not issue cumulative performance data as do NEQAS.


Figures P.26 and P.27 show the relationship between 25-OHD as reported on individual DEQAS samples by the NBA laboratory at HNR and the mean value obtained internationally using the Diasorin Liaison ( $n = \text{approx. } 400$  laboratories), and the relationship between the results obtained in the NBA lab at HNR and the international All Laboratory Trimmed Mean (ALTM,  $n = \text{approx. } 1100$  laboratories).



**Figure P.26 External quality controls for plasma 25OH vitamin D – Years 1 to 4 of the NDNS RP (DEQAS; HNR results versus Liaison method mean)**



**Figure P.27 External quality controls for plasma 25OH vitamin D – Years 1 to 4 of the NDNS RP (DEQAS; HNR results versus ALTM)**



### **P.2.15 Plasma creatinine**

The creatinine method used in the NDNS RP employs a modification of the kinetic Jaffe reaction reported by Larsen.

Under alkaline conditions, creatinine reacts with picrate to form a red chromophore. The rate of increasing absorbance at 510nm due to the formation of this chromophore is directly proportional to the creatinine concentration in the sample and is measured using a bichromatic (510nm, 600nm) rate technique. Bilirubin is oxidised by potassium ferricyanide to prevent interference. This method has been reported to be less susceptible than conventional methods to interference from non-creatinine, Jaffe-positive compounds, however plasma which has been in contact with blood cells for more than 8 hours before separation is not suitable for analysis.

#### **P.2.15.1 Internal quality controls for plasma creatinine**

Multiquant QC samples containing low, moderate and high concentrations of creatinine are run with each sample set. If the results obtained are not within manufacturer's range and also within the range determined within our laboratory, the run is rejected. Table P.66 shows internal QC results for creatinine, covering the period when NDNS Year 1 and Year 2 samples were analysed and Tables P.67-P.68 show internal QC results for creatinine, covering the period when NDNS Years 3 and 4 samples were analysed, respectively.

**Table P.66 Internal quality controls for plasma creatinine for Year 1 and Year 2 of the NDNS RP**

	Low	Medium	High
Mean creatinine $\mu\text{mol/L}$	62.9	170.7	607.1
SD $\mu\text{mol/L}$	4.2	3.0	13.0
CV %	6.7	1.7	2.1
N	36	36	33

**Table P.67 Internal quality controls for plasma creatinine for Year 3 of the NDNS RP**

	Low		Medium		High	
Mean creatinine $\mu\text{mol/L}$	69.2	65.3	169.4	166.2	578.6	588.7
SD $\mu\text{mol/L}$	4.0	3.3	4.9	4.8	13.0	18.1
CV %	5.8	5.1	2.9	2.9	2.2	3.1
N	34	41	36	31	32	45


**Table P.68 Internal quality controls for plasma creatinine for Year 4 of the NDNS RP**

	Low	Medium	High
Mean creatinine $\mu\text{mol/L}$	63.2	164.5	575.2
SD $\mu\text{mol/L}$	4.1	4.7	9.7
CV %	6.5	2.9	1.7
N	43	43	42


*P.2.15.2 External quality controls for plasma creatinine*

HNR subscribes to the UKNEQAS clinical chemistry. Figure P.28 is the UKNEQAS results for creatinine distributions 858 (19 April 2010) to 869 (4 October 2010). This covers the period when Year 1 and Year 2 creatinine retrospective reassay was performed and include an estimate of bias with respect to the All Laboratory Trimmed Mean (B score) and the consistency of that bias (C score). Results within the white area of the resulting chart indicate acceptable performance as determined by UKNEQAS. Figures P.29 and P.30 are the UKNEQAS results for creatinine distributions 867 (August 2010) to 890 (August 2011) and 889 (July 2011) to 911 (August 2102) respectively. These cover the periods when Year 3 and Year 4 creatinine analysis was performed, respectively, and include an estimate of % bias with respect to the All Laboratory Trimmed Mean (average bias = "B score") and the consistency (% CV) of that bias (standard deviation of bias = "C score"). Results within the white area of the resulting chart indicate acceptable performance as determined by UKNEQAS; low scores indicating good performance. The charts below show that HNR's assay is very well controlled in terms both of bias relative to the consensus mean and consistency of that bias.



**Figure P.28 External quality controls for plasma creatinine – Year 1 and Year 2 of the NDNS RP (Bias and Consistency)**



**Figure P.29 External QC for creatinine – performance during Year 3 of the NDNS RP (Bias and Consistency)**



**Figure P.30 External QC for creatinine – performance during Year 4 of the NDNS RP  
(Bias and Consistency)**



### **P.2.16 Selenium and zinc**

Total selenium (Se) and zinc (Zn) concentrations of human blood plasma were determined by measuring the  $^{78}\text{Se}$  and  $^{68}\text{Zn}$  isotopes using an inductively coupled plasma mass spectrometer (ICP-MS) equipped with a dynamic reaction cell (DRC). Methane ( $\text{CH}_4$ ) was used as a DRC gas to overcome Argon based interferences which specifically affect Se measurement. Samples were introduced to the ICP-MS via a V-groove nebuliser and cyclonic spray chamber arrangement.

Human blood plasma samples and quality control (QC) materials were prepared in diluent which included rhodium (Rh) as internal standard. The Se and Zn isotope signals were compared against the internal standard, enabling any signal fluctuation due to instrument drift to be accounted for.

Matrix matched external calibration standards were prepared in commercially prepared calf serum (Sigma Aldrich) for each analytical batch.

Prior to analysis the ICP-MS instrument was tuned for optimum signal sensitivity and minimum oxide species and doubly charged ion formation. Unknown samples, blanks, calibration standards and QCs were analysed in each batch and the signal data generated was converted to concentration data via the calibration plot.

#### *P.2.16.1 Quality controls for selenium and zinc*

In order to establish quality assurance of each analytical batch and inter-batch variation across the year's cohort as a whole, ClinChek Plasma Control Lyophilised for Trace Elements Level 1 and 2 (Recipe Chemicals and Instruments GmbH) QC samples were analysed in conjunction with the blanks, calibration standards and samples.

##### *P.2.16.1.1 Inter-batch variability*

Tables P.69 to P.72 summarise the measured concentration of selenium and zinc following analysis of these QC samples for each individual year of the NDNS RP. For each year the mean measured concentration of the QC was within the target concentration range defined by the manufacturer and CV was  $\leq 10\%$  for each of the



years described, showing that for each year there was acceptable analytical accuracy and precision.

**Table P.69 QC analysis for Year 1 of the NDNS RP**

	ClinChek L1		ClinChek L2	
	Selenium	Zinc	Selenium	Zinc
Lot number	906		906	
Target Concentration /Range (µg/L)	81.0 (64.8-97.2)	1417 (1134-1700)	118 (94.4-142)	1826 (1552-2100)
Mean Measured Concentration (µg/L)	81.7	1438	118	1835
N (QC samples)	55	48	55	48
SD	4.0	63	5	55
%CV	5	4	5	3

**Table P.70 QC analysis for Year 2 of the NDNS RP**

	ClinChek L1		ClinChek L2	
	Selenium	Zinc	Selenium	Zinc
Lot number	906		906	
Target Concentration /Range (µg/L)	81.0 (64.8-97.2)	1417 (1134-1700)	118 (94.4-142)	1826 (1552-2100)
Mean Measured Concentration (µg/L)	84.1	1552	121	2023
N (QC samples)	56	62	56	62
SD	4	100	5	201
%CV	5	6	4	10

**Table P.71 QC analysis for Year 3 of the NDNS RP**

	ClinChek L1		ClinChek L2	
	Selenium	Zinc	Selenium	Zinc
Lot number	906		906	
Target Concentration /Range (µg/L)	81.0 (64.8-97.2)	1417 (1134-1700)	118 (94.4-142)	1826 (1552-2100)
Mean Measured Concentration (µg/L)	85.4	1356	122	1762
N (QC samples)	41	41	46	45
SD	4.7	137	6	144
%CV	6	10	5	8

**Table P.72 QC analysis for Year 4 of the NDNS RP**

	ClinChek L1		ClinChek L2	
	Selenium	Zinc	Selenium	Zinc
Lot number	906		906	
Target Concentration /Range (µg/L)	81.0 (64.8-97.2)	1417 (1134-1700)	118 (94.4-142)	1826 (1552-2100)
Mean Measured Concentration (µg/L)	81.8	1444	119	1888
N (QC samples)	42	42	42	42
SD	5.6	79	9	111
%CV	7	5	7	6

#### *P.2.16.1.2 Inter-year variability*

Assessment of inter-year variability is achieved by comparing the annual mean QC sample results over Years 1 to 4 of the NDNS RP.

Table P.73 shows the mean measured concentration data for Se and Zn analysis of the same QC material for each year of the programme and that inter-year variability is low with CV being 2% for selenium and 6% for zinc.

**Table P.73 Quality control analysis over Years 1 to 4 of the NDNS RP**

	ClinChek L1		ClinChek L2	
	Selenium	Zinc	Selenium	Zinc
Lot number	906		906	
Target Concentration /Range (µg/L)	81.0 (64.8-97.2)	1417 (1134-1700)	118 (94.4-142)	1826 (1552-2100)
	Mean measured concentration (µg/L)			
Year 1	81.7	1438	118	1835
Year 2	84.1	1552	121	2023
Year 3	85.4	1356	122	1762
Year 4	81.8	1444	119	1888
<b>Mean (Years 1-4)</b>	<b>83.3</b>	<b>1448</b>	<b>120</b>	<b>1877</b>
<b>SD</b>	<b>1.8</b>	<b>80</b>	<b>2</b>	<b>110</b>
<b>%CV</b>	<b>2</b>	<b>6</b>	<b>2</b>	<b>6</b>

### *P.2.16.2 External quality controls for selenium and zinc in serum*

HNR participates in the Interlaboratory Comparison Program for Metals in Biological Matrices (PCI), operated by Centre de toxicologie du Québec at the Institut national de santé publique du Québec (INSPQ). Selenium and zinc analysis of serum samples gives values which are within the criteria defined in this multi-laboratory programme.

Note: at the method dilution used there is no significant difference between serum and plasma as a biological matrix and use of these external quality controls is valid.

**Table P.74 QC analysis for Year 4 of the NDNS RP**

	ClinChek L1		ClinChek L2	
	Selenium	Zinc	Selenium	Zinc
Lot number	906		906	
Target Concentration /Range (µg/L)	81.0 (64.8-97.2)	1417 (1134-1700)	118 (94.4-142)	1826 (1552-2100)
Mean Measured Concentration (µg/L)	81.8	1444	119	1888
N	42	42	42	42
SD	5.6	79	9	111
%CV	6.9	5	7	6

#### *P.2.16.2.1 Inter-batch variability*

Assessment of inter-batch variability is achieved by comparing the mean QC sample analysis over these four years of the rolling programme.

Table P.75 shows the mean measured concentration data for Se and Zn analysis of the same QC material for each year of the programme. Overall calculated concentrations are within 2 SD of the manufacture's target, inter-batch variability is low with CV <3% for selenium and <6% for zinc.

**Table P.75 QC analysis over Years 1 to 4 of the NDNS RP**

	ClinChek L1		ClinChek L2	
	Selenium	Zinc	Selenium	Zinc
Lot number	906		906	
Target Concentration /Range (µg/L)	81.0 (64.8-97.2)	1417 (1134-1700)	118 (94.4-142)	1826 (1552-2100)
	Mean measured concentration (µg/L)			
Year 1	81.7	1438	118	1835
Year 2	84.1	1552	121	2023
Year 3	85.4	1356	122	1762
Year 4	81.8	1444	119	1888
<b>Overall (Years 1-4)</b>	<b>83.3</b>	<b>1448</b>	<b>120</b>	<b>1877</b>
<b>Overall SD</b>	<b>1.8</b>	<b>80</b>	<b>2</b>	<b>110</b>
<b>Overall %CV</b>	<b>2.2</b>	<b>6</b>	<b>2</b>	<b>6</b>

### **P.3 Acknowledgements**

We are indebted to the personnel at the following institutions for their assistance in local sample processing and storage:

Abertawe Bro Morgannwg University Health Board; Aintree University Hospitals NHS Foundation Trust; Basildon and Thurrock General Hospitals NHS Trust; Belfast Health and Social Care Trust; Betsi Cadwaldr University Health Board; BMI The Chaucer Hospital (Canterbury); Brighton and Sussex University Hospitals NHS Trust; Calderdale and Huddersfield NHS Foundation Trust; Cancer Research UK Clinical Centre, St James's University Hospital; Cardiff and Vale University Health Board; Clinicheck (London); Colchester Hospital University NHS Foundation Trust; Countess of Chester NHS Foundation Trust; Coventry and Warwickshire University Hospitals NHS Trust; Cwm Taf Health Board; Dartford and Gravesham NHS Trust; Derby Hospitals NHS Foundation Trust; East and North Hertfordshire NHS Trust; East Cheshire NHS Trust; East Sussex Healthcare NHS Trust; Great Western Hospitals NHS Foundation Trust; Harrogate and District NHS Foundation Trust; Homerton University Hospital NHS Foundation Trust; Hull and East Yorkshire Hospitals NHS Trust; Hywel Dda Health Board; Kingston Hospital NHS Trust; Midland Pathology Services (Birmingham); Milton Keynes Hospital NHS Foundation Trust; MRC Human Nutrition Research; NationWide Laboratories (Poulton-le-Fylde); NHS Arran and Ayrshire; NHS Borders; NHS Dumfries and Galloway; NHS Fife; NHS Highland; NHS Isle of Wight; NHS Lanarkshire; NHS Lothian; NHS Shetland; NHS Western Isles; Norfolk and Norwich University Hospital NHS Trust; North Cumbria University Hospitals NHS Trust; North Devon Healthcare NHS Trust; Northern Lincolnshire and Goole Hospitals NHS Foundation Trust; Nuffield Health Exeter Hospital; Nuffield Health Glasgow Hospital; Nuffield Health Newcastle Upon Tyne Hospital; Nuffield Health Tunbridge Wells Hospital; Nuffield Health Wessex Hospital; Nuffield Health Wolverhampton Hospital; Oxford Radcliffe Hospitals NHS Trust; Peterborough and Stamford Hospitals NHS Foundation Trust; Royal Cornwall Hospitals NHS Trust; Salisbury NHS Foundation Trust; Sheffield Hallam University; Source BioScience (Nottingham); South Devon Healthcare NHS Foundation Trust; South London Healthcare NHS Trust; South Tees NHS Foundation Trust; Spire Bristol Hospital; Spire Bushey Hospital; Spire Gatwick Park Hospital; Spire

Southampton Hospital; Spire Portsmouth Hospital; Taunton and Somerset NHS Foundation Trust; The Dudley Group of Hospitals NHS Foundation Trust; The Hillingdon Hospitals NHS Foundation Trust; The Mid Yorkshire Hospitals NHS Trust; The Pennine Acute Hospitals NHS Trust; The Princess Alexandra Hospital NHS Trust; The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust; The Yorkshire Clinic (Bingley); University Hospital of North Staffordshire NHS Trust; University Hospitals of Leicester NHS Trust; University of Aberdeen Rowett Institute of Nutrition and Health; University of Dundee; University of Surrey; Wellcome Trust Clinical Research Facility (Manchester); Western Health and Social Care Trust; Worcestershire Hospitals NHS Trust; Wye Valley NHS Trust and York Teaching Hospital NHS Foundation Trust.

---

<sup>1</sup> Coulter WH. High speed automatic blood cell counter and cell size analyzer. Paper presented at National Electronics Conference, Chicago, IL, 1956; October 3.

<sup>2</sup> Brecher G, Schneiderman M and Williams GZ. Evaluation of electronic red blood cell counter. *American Journal of Clinical Pathology*, 1956; 26:1439-1449.

<sup>3</sup> Stadtman TC. In: Colowick SP, Caplan SO, eds. *Methods in enzymology*, vol III. New York, Academy Press, 1957:392-4 & 67-81.

<sup>4</sup> Rautela GS, Liedtke RJ. Automated enzymatic measurement of total cholesterol in serum. *Clinical chemistry*, 1978, 24:108-14.

<sup>5</sup> Vuilleumier JP, Keck E. Fluorometric assay of vitamin C in biological materials using a centrifugal analyser with fluorescence attachment. *Journal of Micronutrient Analysis*, 1989; 5: 25-34.

<sup>6</sup> Vuilleumier JP, Keller HE, Keck E. Clinical chemical methods for the routine assessment of the vitamin Status in human populations. Part III: The apoenzyme stimulation tests for vitamin B1, B2 and B6. adapted to the Cobas Bio. *International Journal of Vitamin Research*, 1990; 60:126-135.

<sup>7</sup> Glatzle D, Körner WF, Christeller S, Wiss O. Method for the detection of a biochemical riboflavin deficiency stimulation of NADPH2-dependent glutathione reductase from human erythrocytes by FAD *in vitro*: Investigations on the vitamin B2 status in healthy people and geriatric patients. *International Journal of Vitamin Research*, 1970; 40:166-183.

<sup>8</sup> Rybak ME, Pfeiffer CM. Clinical analysis of vitamin B6: Determination of pyridoxal 5-phosphate and 4-pyridoxic acid in human serum by reversed-phase high-performance liquid chromatography with chlorite postcolumn derivatization. *Analytical Biochemistry* 2004; 333:336-344.

<sup>9</sup> Thurnham DI, Smith E, Flora PS. Concurrent liquid-chromatographic assay of retinol, alpha-tocopherol, beta-carotene, alpha-carotene, lycopene, and beta-cryptoxanthin in plasma, with tocopherol acetate as internal standard. *Clinical Chemistry*, 1988; 34(2):377-381.

<sup>10</sup> Rustin D, Hoare J, Henderson L, Gregory J, Bates CJ, Prentice A, Birch M. National Diet and Nutrition Survey: adults aged 19 to 64 years. Volume 4: Nutritional status (anthropometry and blood

---

analytes), blood pressure and physical activity. London: TSO, 2004.

<http://multimedia.food.gov.uk/multimedia/pdfs/ndnsfour.pdf> (accessed 19/03/14).

<sup>11</sup> Gregory J, Lowe S, Bates CJ, Prentice A, Jackson LV, Smithers G, Wenlock, R, Farron M. National Diet and Nutrition Survey: young people aged 4 to 18 years.

Volume 1: Report of the diet and nutrition survey. TSO (London, 2000).

<http://www.food.gov.uk/multimedia/pdfs/ndnsprintedreport.pdf> (accessed 19/03/14).

<sup>12</sup> Finch S, Doyle W, Lowe C, Bates CJ, Prentice A, Smithers G, Clarke PC. National Diet and Nutrition Survey: people aged 65 years and over. Volume 1: Report of the diet and nutrition survey.

London: TSO, 1998. <http://www.esds.ac.uk/findingData/snDescription.asp?sn=4036> (accessed 19/03/14).

<sup>13</sup> Gregory JR, Collins DL, Davies PSW, Hughes JM, Clarke PC. National Diet and Nutrition Survey: children aged 1 ½ to 4 ½ years. Volume 1: Report of the diet and nutrition survey London: HMSO, 1995.